^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Eylea (aflibercept intravitreal)

    i
    Other names: BAY86-5321, AVE0005, AVE-0005, VEGF Trap-Eye, AVE 0005, BAY865321, BAY86 5321
    Company:
    Bayer, Chong Kun Dang, Regeneron
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor
    Related drugs:
    1d
    AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema (2025-522231-34-00)
    P2/3, N=172, Not yet recruiting, Alvotech Swiss AG | N=102 --> 172
    Enrollment change
    |
    Eylea (aflibercept intravitreal)
    3d
    A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU) (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Exegenesis Bio | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    3d
    EYP-1901-303: COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (2025-523937-25-00)
    P2/3, N=37, Not yet recruiting, Eyepoint Pharmaceuticals Inc.
    New P2/3 trial
    |
    Eylea (aflibercept intravitreal)
    10d
    EYP-1901-304: CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (2025-523938-10-00)
    P2/3, N=50, Not yet recruiting, Eyepoint Pharmaceuticals Inc.
    New P2/3 trial
    |
    Eylea (aflibercept intravitreal)
    11d
    PHOTONiC: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=333, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    12d
    Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Sam Chun Dang Pharm. Co. Ltd.
    New P2 trial
    |
    Eylea (aflibercept intravitreal)
    17d
    4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=480, Active, not recruiting, 4D Molecular Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    18d
    A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P3, N=356, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    19d
    ALVOEYE-HD: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=256, Not yet recruiting, Alvotech Swiss AG
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    23d
    Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (clinicaltrials.gov)
    P3, N=284, Recruiting, Adverum Biotechnologies, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    26d
    COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (clinicaltrials.gov)
    P3, N=240, Recruiting, EyePoint Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    27d
    When the Air Gets Thin, and the Blood Gets Thick: Choroidal Hemangioma in High-Altitude Polycythemia. (PubMed, Cureus)
    The patient also received a single intravitreal Eylea (aflibercept) injection, following which the subretinal fluid subsided significantly...Chronic hypoxia-induced hyperviscosity may contribute to vascular dilation and permeability changes within the choroid. Recognition of this association is crucial for timely diagnosis and effective management of choroidal hemangioma to preserve vision.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Eylea (aflibercept intravitreal)